|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Mauna Kea Technologies |
|---|---|
| Collaborators: |
Cellvizio Inc. Emissary International LLC |
| Information provided by: | Mauna Kea Technologies |
| ClinicalTrials.gov Identifier: | NCT00795184 |
Purpose
This study will collect data from patients routinely undergoing a endoscopic surveillance and Cellvizio endomicroscopy procedure due to confirmed Barrett's esophagus. The objective is to determine if endomicroscopy images collected using the marketed Cellvizio device may help endoscopists more accurately diagnose, in conjunction with traditional tissue sampling techniques, whether a suspected lesion is malignant or benign.
| Condition | Intervention |
|---|---|
|
Barrett Syndrome Barrett's Syndrome Barrett's Esophagus Barrett Esophagus Adenocarcinoma |
Device: Probe-based confocal laser endomicroscopy Device: Narrow Band Imaging (NBI) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Investigator, Outcomes Assessor) Primary Purpose: Diagnostic |
| Official Title: | Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy |
| Enrollment: | 110 |
| Study Start Date: | November 2008 |
| Study Completion Date: | February 2010 |
| Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.
Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.
Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.
After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.
All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.
Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.
Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.
After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.
This is a cross-over tandem study to directly address the low sensitivity and specificity of enhanced macroscopic endoscopic imaging devices by determining whether probe-based Confocal Laser Endomicroscopy (pCLE), as a supplement to Narrow Band Imaging (NBI) can further improve sensitivity and specificity to a level that would be acceptable to avoid random biopsy, and better direct biopsy of suspicious areas. The study is also addressing pCLE as a supplement to standard white light endoscopy and random biopsy alone. In fact, the study is powered to evaluate per lesion sensitivity and specificity of confocal imaging as applied to lesions identified by white light endoscopy. Therefore, the study addresses the shortcomings of standard white light endoscopy (high number of random biopsies, less than ideal directed biopsy of suspicious areas) and the primary shortcomings of NBI (low specificity with resultant high false positives, again resulting in many unnecessary biopsies).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Florida | |
| Mayo Clinic | |
| Jacksonville, Florida, United States, 32224 | |
| United States, Missouri | |
| Veterans Affairs Hospital | |
| Kansas City, Missouri, United States, 64128 | |
| United States, New York | |
| New York Presbyterian Hospital/Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| France | |
| Centre Hospitalier Universitaire | |
| Nantes, France, 44093 Cedex 1 | |
| Germany | |
| Klinikum rechts der Isar | |
| Munich, Bayern, Germany | |
| Principal Investigator: | Prateek Sharma, MD | Veterans Affairs Hospital, Kansas City |
More Information
| Responsible Party: | Anne Osdoit / Clinical Affairs Manager, Mauna Kea Technologies |
| ClinicalTrials.gov Identifier: | NCT00795184 History of Changes |
| Other Study ID Numbers: | MKT-2008-BE-01 |
| Study First Received: | November 20, 2008 |
| Last Updated: | March 11, 2010 |
| Health Authority: | United States: Institutional Review Board; Germany: Ethikkommission der Fakultät für Medizin der Technischen Universität München |
|
Barrett's Esophagus EsoGastroDuodenoscopy Barrett's Carcinoma adenocarcinoma |
Cellvizio endomicroscopy random biopsy |
|
Adenocarcinoma Barrett Esophagus Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Digestive System Abnormalities Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases |